Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Amortization of Deferred Charges: 2022-2023

  • Whitehawk Therapeutics' Amortization of Deferred Charges rose 54.41% to -$486,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$2.3 million, marking a year-over-year change of. This contributed to the annual value of -$3.1 million for FY2023, which is 158.11% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Amortization of Deferred Charges of -$486,000 as of Q4 2023, which was up 17.35% from -$588,000 recorded in Q3 2023.
  • In the past 5 years, Whitehawk Therapeutics' Amortization of Deferred Charges registered a high of -$149,000 during Q3 2022, and its lowest value of -$1.1 million during Q4 2022.
  • Moreover, its 2-year median value for Amortization of Deferred Charges was -$537,000 (2023), whereas its average is -$572,250.
  • Within the past 5 years, the most significant YoY rise in Whitehawk Therapeutics' Amortization of Deferred Charges was 54.41% (2023), while the steepest drop was 294.63% (2023).
  • Quarterly analysis of 2 years shows Whitehawk Therapeutics' Amortization of Deferred Charges stood at -$1.1 million in 2022, then surged by 54.41% to -$486,000 in 2023.
  • Its Amortization of Deferred Charges stands at -$486,000 for Q4 2023, versus -$588,000 for Q3 2023 and -$1.1 million for Q4 2022.